Moderna Cancer Vaccine

A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return. Drugmakers Moderna and Merck announced the results Thursday. The vaccine was custom-brewed for each patient to match their tumor. It teaches the patient’s immune system to watch out for and attack any cancer cells that start forming again. Adding it to a standard post-surgery treatment reduced by 42% the risk of melanoma returning two years after surgery, according to the most advanced study to date.